Simon Quick Advisors LLC Has $901,000 Holdings in Amgen Inc. (NASDAQ:AMGN)

Simon Quick Advisors LLC boosted its position in shares of Amgen Inc. (NASDAQ:AMGN) by 22.1% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,882 shares of the medical research company’s stock after acquiring an additional 521 shares during the period. Simon Quick Advisors LLC’s holdings in Amgen were worth $901,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in AMGN. Aveo Capital Partners LLC raised its stake in Amgen by 19.9% during the 4th quarter. Aveo Capital Partners LLC now owns 2,729 shares of the medical research company’s stock valued at $786,000 after purchasing an additional 453 shares during the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management increased its holdings in shares of Amgen by 12.7% during the 4th quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 5,638 shares of the medical research company’s stock worth $1,624,000 after purchasing an additional 637 shares during the period. Gryphon Financial Partners LLC raised its position in shares of Amgen by 295.3% during the fourth quarter. Gryphon Financial Partners LLC now owns 3,684 shares of the medical research company’s stock valued at $1,021,000 after buying an additional 2,752 shares during the last quarter. US Asset Management LLC bought a new stake in shares of Amgen in the fourth quarter valued at about $632,000. Finally, Kessler Investment Group LLC grew its position in Amgen by 1.6% during the fourth quarter. Kessler Investment Group LLC now owns 4,383 shares of the medical research company’s stock worth $1,262,000 after buying an additional 68 shares in the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on AMGN. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a $305.00 price objective (down previously from $310.00) on shares of Amgen in a research report on Wednesday, August 7th. Bank of America lifted their price target on shares of Amgen from $325.00 to $330.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 7th. Wells Fargo & Company cut shares of Amgen from an “overweight” rating to an “equal weight” rating and increased their price objective for the company from $320.00 to $335.00 in a research note on Wednesday, August 7th. Royal Bank of Canada lifted their target price on shares of Amgen from $332.00 to $362.00 and gave the company an “outperform” rating in a research report on Wednesday, August 7th. Finally, Morgan Stanley lowered their target price on shares of Amgen from $310.00 to $303.00 and set an “equal weight” rating on the stock in a research note on Thursday, July 11th. Eleven equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $326.89.

Amgen Stock Up 0.0 %

Shares of NASDAQ AMGN opened at $330.64 on Thursday. Amgen Inc. has a 12-month low of $248.38 and a 12-month high of $346.85. The firm’s 50-day simple moving average is $325.89 and its 200 day simple moving average is $301.70. The company has a quick ratio of 0.89, a current ratio of 1.26 and a debt-to-equity ratio of 9.64. The company has a market cap of $177.37 billion, a price-to-earnings ratio of 47.23, a price-to-earnings-growth ratio of 2.96 and a beta of 0.58.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, August 6th. The medical research company reported $4.97 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.01 by ($0.04). The company had revenue of $8.39 billion for the quarter, compared to analyst estimates of $8.35 billion. Amgen had a return on equity of 161.72% and a net margin of 10.12%. Amgen’s revenue for the quarter was up 20.1% on a year-over-year basis. During the same quarter in the previous year, the company posted $5.00 earnings per share. On average, research analysts expect that Amgen Inc. will post 19.49 earnings per share for the current fiscal year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, August 6th. Stockholders of record on Friday, August 16th were given a dividend of $2.25 per share. The ex-dividend date of this dividend was Friday, August 16th. This represents a $9.00 dividend on an annualized basis and a dividend yield of 2.72%. Amgen’s payout ratio is currently 128.57%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.